These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24837431)

  • 81. Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.
    Brockhoff M; Rion N; Chojnowska K; Wiktorowicz T; Eickhorst C; Erne B; Frank S; Angelini C; Furling D; Rüegg MA; Sinnreich M; Castets P
    J Clin Invest; 2017 Feb; 127(2):549-563. PubMed ID: 28067669
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity.
    Li M; Khambu B; Zhang H; Kang JH; Chen X; Chen D; Vollmer L; Liu PQ; Vogt A; Yin XM
    J Biol Chem; 2013 Dec; 288(50):35769-80. PubMed ID: 24174532
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Role of mTOR, Bad, and Survivin in RasGAP Fragment N-Mediated Cell Protection.
    Peltzer N; Vanli G; Yang JY; Widmann C
    PLoS One; 2013; 8(6):e68123. PubMed ID: 23826368
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Fisetin regulates obesity by targeting mTORC1 signaling.
    Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
    J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
    [TBL] [Abstract][Full Text] [Related]  

  • 85. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
    Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
    Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Basement Membrane Laminin α2 Regulation of BTB Dynamics via Its Effects on F-Actin and Microtubule Cytoskeletons Is Mediated Through mTORC1 Signaling.
    Gao Y; Chen H; Lui WY; Lee WM; Cheng CY
    Endocrinology; 2017 Apr; 158(4):963-978. PubMed ID: 28323988
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
    Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
    J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Vegf signaling promotes vascular endothelial differentiation by modulating etv2 expression.
    Casie Chetty S; Rost MS; Enriquez JR; Schumacher JA; Baltrunaite K; Rossi A; Stainier DY; Sumanas S
    Dev Biol; 2017 Apr; 424(2):147-161. PubMed ID: 28279709
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Deficiency in mTORC1-controlled C/EBPβ-mRNA translation improves metabolic health in mice.
    Zidek LM; Ackermann T; Hartleben G; Eichwald S; Kortman G; Kiehntopf M; Leutz A; Sonenberg N; Wang ZQ; von Maltzahn J; Müller C; Calkhoven CF
    EMBO Rep; 2015 Aug; 16(8):1022-36. PubMed ID: 26113365
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Regulation of signaling interactions and receptor endocytosis in growing blood vessels.
    Pitulescu ME; Adams RH
    Cell Adh Migr; 2014; 8(4):366-77. PubMed ID: 25482636
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
    Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
    Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
    [TBL] [Abstract][Full Text] [Related]  

  • 92. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
    Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
    PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
    Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
    Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A critical role for mTORC1 in erythropoiesis and anemia.
    Knight ZA; Schmidt SF; Birsoy K; Tan K; Friedman JM
    Elife; 2014 Sep; 3():e01913. PubMed ID: 25201874
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling.
    Sun S; Chen S; Liu F; Wu H; McHugh J; Bergin IL; Gupta A; Adams D; Guan JL
    Cancer Cell; 2015 Dec; 28(6):758-772. PubMed ID: 26777415
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Generation of mice with a conditional allele of the p120 Ras GTPase-activating protein.
    Lapinski PE; Bauler TJ; Brown EJ; Hughes ED; Saunders TL; King PD
    Genesis; 2007 Dec; 45(12):762-7. PubMed ID: 18064675
    [TBL] [Abstract][Full Text] [Related]  

  • 98. mTORC1 Promotes T-bet Phosphorylation To Regulate Th1 Differentiation.
    Chornoguz O; Hagan RS; Haile A; Arwood ML; Gamper CJ; Banerjee A; Powell JD
    J Immunol; 2017 May; 198(10):3939-3948. PubMed ID: 28424242
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.
    Wang S; Amato KR; Song W; Youngblood V; Lee K; Boothby M; Brantley-Sieders DM; Chen J
    Mol Cell Biol; 2015 Apr; 35(7):1299-313. PubMed ID: 25582201
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations.
    Zhao S; Mekbib KY; van der Ent MA; Allington G; Prendergast A; Chau JE; Smith H; Shohfi J; Ocken J; Duran D; Furey CG; Hao LT; Duy PQ; Reeves BC; Zhang J; Nelson-Williams C; Chen D; Li B; Nottoli T; Bai S; Rolle M; Zeng X; Dong W; Fu PY; Wang YC; Mane S; Piwowarczyk P; Fehnel KP; See AP; Iskandar BJ; Aagaard-Kienitz B; Moyer QJ; Dennis E; Kiziltug E; Kundishora AJ; DeSpenza T; Greenberg ABW; Kidanemariam SM; Hale AT; Johnston JM; Jackson EM; Storm PB; Lang SS; Butler WE; Carter BS; Chapman P; Stapleton CJ; Patel AB; Rodesch G; Smajda S; Berenstein A; Barak T; Erson-Omay EZ; Zhao H; Moreno-De-Luca A; Proctor MR; Smith ER; Orbach DB; Alper SL; Nicoli S; Boggon TJ; Lifton RP; Gunel M; King PD; Jin SC; Kahle KT
    Nat Commun; 2023 Nov; 14(1):7452. PubMed ID: 37978175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.